Kashiv BioSciences

Kashiv BioSciences is recorded here as a biopharmaceutical company brand. However, the evidence supplied for this task does not contain any material about the company: the two snippets are Chinese-language news articles, one about an agricultural AI model for soybean breeding released by Anhui Agricultural University and the Chinese Academy of Agricultural Sciences, and the other about livestream commerce and brand strategy during a Chinese shopping festival. Neither mentions Kashiv BioSciences, its products, ownership, leadership, or history. Because the source material is unrelated to the subject, this dossier deliberately stays minimal rather than filling gaps with unverified assumptions. No founding year, headquarters, founder, parent company, website, product list, executive, or financial detail is asserted here, since none can be grounded in the supplied evidence. The entry is flagged for review so that a researcher can attach proper sources — for example the company's own website, regulatory filings, or press releases — before the profile is expanded. Once reliable sources are available, this record should be developed around the company's therapeutic areas, pipeline and commercial products, manufacturing footprint, partnerships, and corporate ownership.

• 2026-08-10

  Amneal Pharmaceuticals completes acquisition of Kashiv BioSciences[3]Amneal Pharmaceuticals完成对Kashiv BioSciences的收购mondaq.com

  Reported: 2026-08-17

  Amneal Pharmaceuticals completed its acquisition of Kashiv BioSciences for up to $1.1 billion, creating a fully integrated global biosimilars platform. Terms included $375 million in cash, $375 million in equity at closing, and up to $350 million in additional milestone and contingent payments.

1. 1我国科学家发布大豆垂直大模型“丰菽”2.0，推动实现辅助育种_网易订阅163.com
2. 2直播退烧，品牌迎来梦醒时分|天猫|电商|退货率|三只松鼠|集团总收入_网易订阅163.com
3. 3Amneal Pharmaceuticals完成对Kashiv BioSciences的收购mondaq.com